Literature DB >> 30863885

A simple and practical index predicting the prognoses of the patients with well-differentiated pancreatic neuroendocrine neoplasms.

Bo Liu1, Atsushi Kudo2, Yuko Kinowaki3, Toshiro Ogura1, Kosuke Ogawa1, Hiroaki Ono1, Yusuke Mitsunori1, Daisuke Ban1, Shinji Tanaka4, Takumi Akashi3, Minoru Tanabe1.   

Abstract

BACKGROUND: The prognostic importance of the neuroendocrine (NE) markers involving neural cell adhesion molecule (NCAM) has been unclear enough to be adopted for WHO classification in patients with pancreatic neuroendocrine neoplasms (Pan-NENs). This study aimed to elucidate whether the three NE markers such as chromogranin A, synaptophysin, and NCAM decide prognoses for patients with well-differentiated tumors.
METHODS: Between April 2002 and October 2018, 217 patients were included in this study. Tissue samples from tumors of Pan-NENs were immunochemically stained for the aforementioned NE markers. Diffuse and intense staining was defined as positive, while faint or focal staining and non-staining were considered negative.
RESULTS: The median age of patients was 55 years. The median observation period was 1415 days. In multivariate analysis of progression-free survival (PFS), liver metastasis, Ki-67 index, and triple-positive staining of NE markers were risk factors. The 5-year PFS rate of patients with and without triple-positive NE markers was 56.3% and 23.8%, respectively (P < 0.0001). In multivariate analysis of overall survival (OS), R0 resection, Ki-67 index and triple-positive NE markers (hazard ratio 0.4, P = 0.02) were the risk factors. The 5-year OS rate of patients with and without triple-positive NE markers was 88.8% and 66.4%, respectively (P = 0.014). The tumors of patients without triple-positive NE markers were associated with large tumor size, a high mitotic rate and high Ki-67 index.
CONCLUSIONS: Triple-positive NE marker staining was a simple and practical indicator of prognoses in patients with well-differentiated Pan-NETs.

Entities:  

Keywords:  CD56; NCAM; Pancreatic neuroendocrine neoplasms; Simple index

Mesh:

Substances:

Year:  2019        PMID: 30863885     DOI: 10.1007/s00535-019-01570-0

Source DB:  PubMed          Journal:  J Gastroenterol        ISSN: 0944-1174            Impact factor:   7.527


  28 in total

1.  Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors.

Authors:  Shinichi Yachida; Efsevia Vakiani; Catherine M White; Yi Zhong; Tyler Saunders; Richard Morgan; Roeland F de Wilde; Anirban Maitra; Jessica Hicks; Angelo M Demarzo; Chanjuan Shi; Rajni Sharma; Daniel Laheru; Barish H Edil; Christopher L Wolfgang; Richard D Schulick; Ralph H Hruban; Laura H Tang; David S Klimstra; Christine A Iacobuzio-Donahue
Journal:  Am J Surg Pathol       Date:  2012-02       Impact factor: 6.394

2.  Aggressive surgery improves long-term survival in neuroendocrine pancreatic tumors: an institutional experience.

Authors:  Paulus G Schurr; Tim Strate; Kim Rese; Jussuf T Kaifi; Uta Reichelt; Susanne Petri; Helge Kleinhans; Emre F Yekebas; Jakob R Izbicki
Journal:  Ann Surg       Date:  2007-02       Impact factor: 12.969

3.  Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases.

Authors:  W Kimura; A Kuroda; Y Morioka
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

4.  Prognostic factors in pancreatic endocrine neoplasms: an analysis of 136 cases with a proposal for low-grade and intermediate-grade groups.

Authors:  Steven N Hochwald; Sui Zee; Kevin C Conlon; Roberto Colleoni; Otway Louie; Murray F Brennan; David S Klimstra
Journal:  J Clin Oncol       Date:  2002-06-01       Impact factor: 44.544

5.  Differences in survival by histologic type of pancreatic cancer.

Authors:  Megan Dann Fesinmeyer; Melissa A Austin; Christopher I Li; Anneclaire J De Roos; Deborah J Bowen
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2005-07       Impact factor: 4.254

Review 6.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

7.  Determining prognosis in patients with pancreatic endocrine neoplasms: can the WHO classification system be simplified?

Authors:  Cristina R Ferrone; Laura H Tang; James Tomlinson; Mithat Gonen; Steven N Hochwald; Murray F Brennan; David S Klimstra; Peter J Allen
Journal:  J Clin Oncol       Date:  2007-12-10       Impact factor: 44.544

8.  Immunohistochemical analysis of neural cell adhesion molecules. Differential expression in small round cell tumors of childhood and adolescence.

Authors:  P Garin-Chesa; E J Fellinger; A G Huvos; H R Beresford; M R Melamed; T J Triche; W J Rettig
Journal:  Am J Pathol       Date:  1991-08       Impact factor: 4.307

9.  CD56 expression of neuroendocrine neoplasms on immunophenotyping by flow cytometry: a novel diagnostic approach to fine-needle aspiration biopsy.

Authors:  Maryam A Farinola; Edward G Weir; Syed Z Ali
Journal:  Cancer       Date:  2003-08-25       Impact factor: 6.860

10.  Prognostic score predicting survival after resection of pancreatic neuroendocrine tumors: analysis of 3851 patients.

Authors:  Karl Y Bilimoria; Mark S Talamonti; James S Tomlinson; Andrew K Stewart; David P Winchester; Clifford Y Ko; David J Bentrem
Journal:  Ann Surg       Date:  2008-03       Impact factor: 12.969

View more
  4 in total

1.  Comparison of prognosis between observation and surgical resection groups with small sporadic non-functional pancreatic neuroendocrine neoplasms without distant metastasis.

Authors:  Yusuke Kurita; Kazuo Hara; Takamichi Kuwahara; Nobumasa Mizuno; Nozomi Okuno; Shin Haba; Masataka Okuno; Seiji Natsume; Yoshiki Senda; Kensuke Kubota; Atsushi Nakajima; Yasumasa Niwa; Yasuhiro Shimizu
Journal:  J Gastroenterol       Date:  2019-12-19       Impact factor: 7.527

Review 2.  Systematic Review and Metaanalysis of Lymph Node Metastases of Resected Pancreatic Neuroendocrine Tumors.

Authors:  Masayuki Tanaka; Max Heckler; André L Mihaljevic; Pascal Probst; Ulla Klaiber; Ulrike Heger; Simon Schimmack; Markus W Büchler; Thilo Hackert
Journal:  Ann Surg Oncol       Date:  2020-07-27       Impact factor: 5.344

3.  CD56 Expression Is Associated with Biological Behavior of Pancreatic Neuroendocrine Neoplasms.

Authors:  Xin Chen; Chuangen Guo; Wenjing Cui; Ke Sun; Zhongqiu Wang; Xiao Chen
Journal:  Cancer Manag Res       Date:  2020-06-17       Impact factor: 3.989

4.  Insights of Outcome after Resection of Small Nonfunctioning Neuroendocrine Pancreatic Tumors.

Authors:  Estela Regina Ramos Figueira; Julia Fray Ribeiro; Thiago Costa Ribeiro; Ricardo Jureidini; Guilherme Naccache Namur; Thiago Nogueira Costa; Telesforo Bacchella; Ivan Cecconello
Journal:  Gastroenterol Res Pract       Date:  2021-04-24       Impact factor: 2.260

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.